A phase I study to evaluate the safety/tolerability and immunogenicity of V-930 in patients with cancers expressing HER-2 [human epidermal growth factor receptor-2] and/or CEA [carcinoembryonic antigen]
Phase of Trial: Phase I
Latest Information Update: 17 Oct 2006
At a glance
- Drugs V-930 (Primary)
- Indications Breast cancer; Colorectal cancer; Non-small cell lung cancer; Ovarian cancer
- Focus Adverse reactions
- 17 Oct 2006 New trial record.